Glibenclamide is a hypoglycemic drug that is widely used for the treatment of diabetes mellitus type 2 (DM II), but it also plays a protective role following injury to the central nervous system (CNS). However, the precise mechanisms underlying its neuroprotective actions remain to be elucidated. Therefore, the present study evaluated the effects of glibenclamide on the blood–brain barrier (BBB) in a mouse model of traumatic brain injury (TBI). In the present study, 86 adult male C57BL/6 mice were exposed to a controlled cortical impact (CCI) injury and then received glibenclamide (10 μg) for 3 days. Tight junction (TJ) protein levels, BBB permeability, and tissue hemoglobin levels were evaluated following the CCI injury. Additionally, a biaxial stretch injury was applied to cell cultures of bEnd.3 cells using the Cell Injury Controller II system to explore the mechanisms by which glibenclamide inhibits apoptosis-signaling pathways. Compared with the control group, glibenclamide-treated mice exhibited decreases in brain water content (p < 0.05), tissue hemoglobin levels (p < 0.05), and Evans Blue extravasation (p < 0.01) after the CCI injury. Glibenclamide primarily attenuated apoptosis via the JNK/c-jun signaling pathway and resulted in an elevation of stretch injury-induced ZO-1 expression in bEnd.3 cells (p < 0.01).Glibenclamide downregulated the activity of the JNK/c-jun apoptosis-signaling pathway which, in turn, decreased apoptosis in endothelial cells (ECs). This may have prevented the disruption of the BBB in a mouse model of TBI.
Get full access to this article
View all access options for this article.
References
1.
AndriessenT.M., HornJ., FranschmanG., van der NaaltJ., HaitsmaI., JacobsB., SteyerbergE.W., and VosP.E. (2011). Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study. J. Neurotrauma, 28, 2019–2031.
2.
ThalS.C., SchaibleE.V., NeuhausW., SchefferD., BrandstetterM., EngelhardK., WunderC., and ForsterC.Y. (2013). Inhibition of proteasomal glucocorticoid receptor degradation restores dexamethasone-mediated stabilization of the blood-brain barrier after traumatic brain injury. Crit. Care Med., 41, 1305–1315.
3.
MarklundN., BakshiA., CastelbuonoD.J., ConteV., and McIntoshT.K. (2006). Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr. Pharm. Des., 12, 1645–1680.
RobertsI., YatesD., SandercockP., FarrellB., WasserbergJ., LomasG., CottinghamR., SvobodaP., BrayleyN., MazairacG., LaloeV., Munoz–SanchezA., ArangoM., HartzenbergB., KhamisH., YutthakasemsuntS., KomolafeE., OlldashiF., YadavY., Murillo–CabezasF., ShakurH., EdwardsP., and collaborators (2004). Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet, 364, 1321–1328.
6.
MarbleA. (1971). Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?. Drugs, 1, 109–115.
7.
AshcroftF.M. (1996). Mechanisms of the glycaemic effects of sulfonylureas. Horm. Metab. Res., 28, 456–463.
8.
FeldmanJ.M. (1985). Review of glyburide after one year on the market. Am. J. Med., 79, 102–108.
9.
KramerW., MullerG., GirbigF., GutjahrU., KowalewskiS., HartzD., and SummH.D. (1995). The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Res. Clin. Pract., 28, Suppl., S67–80.
10.
PantenU., SchwanstecherM., and SchwanstecherC. (1996). Sulfonylurea receptors and mechanism of sulfonylurea action. Exp. Clin. Endocrinol., 104, 1–9.
11.
KurlandD.B., TosunC., PamporiA., KarimyJ.K., CaffesN.M., GerzanichV., and SimardJ.M. (2013). Glibenclamide for the treatment of acute CNS injury. Pharmaceuticals, 6, 1287–1303.
12.
PompermayerK., AmaralF.A., FagundesC.T., VieiraA.T., CunhaF.Q., TeixeiraM.M., and SouzaD.G. (2007). Effects of the treatment with glibenclamide, an ATP-sensitive potassium channel blocker, on intestinal ischemia and reperfusion injury. Eur. J. Pharmacol., 556, 215–222.
SimardJ.M., YurovskyV., TsymbalyukN., MelnichenkoL., IvanovaS., and GerzanichV. (2009). Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke, 40, 604–609.
15.
SimardJ.M., TsymbalyukN., TsymbalyukO., IvanovaS., YurovskyV., and GerzanichV. (2010). Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke, 41, 531–537.
16.
SimardJ.M., WooS.K., TsymbalyukN., VoloshynO., YurovskyV., IvanovaS., LeeR., and GerzanichV. (2012). Glibenclamide-10-h treatment window in a clinically relevant model of stroke. Transl. Stroke Res., 3, 286–295.
17.
WaliB., IshratT., AtifF., HuaF., SteinD.G., and SayeedI. (2012). Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. Stroke Res. Treat., 2012, 460909.
18.
SimardJ.M., TsymbalyukO., IvanovA., IvanovaS., BhattaS., GengZ., WooS.K., and GerzanichV. (2007). Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J. Clin. Invest., 117, 2105–2113.
19.
SimardJ.M., WooS.K., NorenbergM.D., TosunC., ChenZ., IvanovaS., TsymbalyukO., BryanJ., LandsmanD., and GerzanichV. (2010). Brief suppression of Abcc8 prevents autodestruction of spinal cord after trauma. Science Transl. Med., 2, 28–29.
20.
SimardJ.M., PopovichP.G., TsymbalyukO., and GerzanichV. (2012). Spinal cord injury with unilateral versus bilateral primary hemorrhage—effects of glibenclamide. Exp. Neurol., 233, 829–835.
21.
SimardJ.M., TsymbalyukO., KeledjianK., IvanovA., IvanovaS., and GerzanichV. (2012). Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. Exp. Neurol., 233, 566–574.
22.
SimardJ.M., KilbourneM., TsymbalyukO., TosunC., CaridiJ., IvanovaS., KeledjianK., BochicchioG., and GerzanichV. (2009). Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J. Neurotrauma, 26, 2257–2267.
23.
PatelA.D., GerzanichV., GengZ., and SimardJ.M. (2010). Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J. Neuropathol. Exp. Neurol., 69, 1177–1190.
SimardJ.M., GengZ., WooS.K., IvanovaS., TosunC., MelnichenkoL., and GerzanichV. (2009). Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab., 29, 317–330.
26.
TosunC., KurlandD.B., MehtaR., CastellaniR.J., deJongJ.L., KwonM.S., WooS.K., GerzanichV., and SimardJ.M. (2013). Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke, 44, 3522–3528.
27.
TosunC., KoltzM.T., KurlandD.B., IjazH., GurakarM., SchwartzbauerG., CoksayganT., IvanovaS., GerzanichV., and SimardJ.M. (2013). The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity. Brain Sci. 3, 215–238.
28.
ZhouY., FathaliN., LekicT., TangJ., and ZhangJ.H. (2009). Glibenclamide improves neurological function in neonatal hypoxia-ischemia in rats. Brain Res. 1270, 131–139.
29.
ThompsonE.M., PishkoG.L., MuldoonL.L., and NeuweltE.A. (2013). Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. Neoplasia, 15, 535–543.
30.
YenariM.A., and HanH.S. (2012). Neuroprotective mechanisms of hypothermia in brain ischaemia. Nat. Rev. Neurosci., 13, 267–278.
31.
JayakumarA.R., ValdesV., TongX.Y., ShamaladeviN., GonzalezW., and NorenbergM.D. (2014). Sulfonylurea receptor 1 contributes to the astrocyte swelling and brain edema in acute liver failure. Transl. Stroke Res., 5, 28–37.
32.
WooS.K., KwonM.S., IvanovA., GerzanichV., and SimardJ.M. (2013). The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. J. Biol. Chem., 288, 3655–3667.
33.
WebsterG.D., RzigalinskiB.A. and GablerH.C. (2008). Development of an improved injury device for neural cell cultures. Biomed. Sci. Instrum., 44, 483–488.
34.
AhmedS.M., RzigalinskiB.A., WilloughbyK.A., SitterdingH.A., and EllisE.F. (2000). Stretch-induced injury alters mitochondrial membrane potential and cellular ATP in cultured astrocytes and neurons. J. Neurochem., 74, 1951–1960.
35.
YuanF., XuZ.M., LuL.Y., NieH., DingJ., YingW.H., and TianH.L. (2016). SIRT2 inhibition exacerbates neuroinflammation and blood–brain barrier disruption in experimental traumatic brain injury by enhancing NF-kappaB p65 acetylation and activation. J. Neurochem., 136, 581–593.
36.
LairdM.D., Sukumari–RameshS., SwiftA.E., MeilerS.E., VenderJ.R., and DhandapaniK.M. (2010). Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4?. J. Neurochem., 113, 637–648.
37.
SinhaK., DasJ., PalP.B., and SilP.C. (2013). Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch. Toxicol., 87, 1157–1180.
38.
RiddleM.C. (2003). Editorial: sulfonylureas differ in effects on ischemic preconditioning—is it time to retire glyburide?. J. Clin. Endocrinol. Metab., 88, 528–530.
39.
KurlandD., HongC., AarabiB., GerzanichV., and SimardJ.M. (2012). Hemorrhagic progression of a contusion after traumatic brain injury: a review. J. Neurotrauma, 29, 19–31.
40.
DhanasekaranD.N., and ReddyE.P. (2008). JNK signaling in apoptosis. Oncogene, 27, 6245–6251.
41.
StarkR.J., ChoiH., KochS.R., FensterheimB.A., LambF.S., and SherwoodE.R. (2016). Endothelial cell tolerance to lipopolysaccharide challenge is induced by monophosphoryl lipid A. Clin. Sci., 130, 451–461.
42.
LiY., CaoY., ZengZ., LiangM., XueY., XiC., ZhouM., and JiangW. (2015). Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-kappaB pathways. Sci. Rep., 5, 8209.
43.
ChenL., WangJ., WangB., YangJ., GongZ., ZhaoX., ZhangC., and DuK. (2016). MiR-126 inhibits vascular endothelial cell apoptosis through targeting PI3K/Akt signaling. Ann. Hematol., 95, 365–374.
44.
TienY.C., LiaoJ.C., ChiuC.S., HuangT.H., HuangC.Y., ChangW.T., and PengW.H. (2011). Esculetin ameliorates carbon tetrachloride-mediated hepatic apoptosis in rats. Int. J. Mol. Sci., 12, 4053–4067.
45.
Abu-QareA.W., and Abou-DoniaM.B. (2001). Biomarkers of apoptosis: release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2'-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J. Toxicol. Environ. Health B Crit. Rev., 4, 313–332.
46.
AnuradhaC.V., and RavikumarP. (2001). Restoration on tissue antioxidants by fenugreek seeds (Trigonella Foenum Graecum) in alloxan-diabetic rats. Indian J. Physiol. Pharmacol., 45, 408–420.
47.
SongJ.S., LeeH.Y., LeeE., HwangH.J., and KimJ.H. (2002). Cytotoxicity and apoptosis induction of sodium fluoride in human promyelocytic leukemia (HL-60) cells. Environ. Toxicol. Pharmacol., 11, 85–91.
